Hazardous biological pathogens in the air pose a significant public environmental health concern as infected individuals emit virus-laden aerosols (VLAs) during routine respiratory activities. Mask-wearing is a key preventive measure, but conventional filtration methods face challenges, particularly in high humidity conditions, where electrostatic charge decline increases the risk of infection. This study introduces a bio-based air filter comprising glycine ionic liquids (GILs) and malleable polymer composite (GILP) with high polarity and functional group density, which are wrapped around a melamine-formaldehyde (MF) resin skeleton, forming a conductive, porous GIL functionized ionic network air filter (GILP@MF). When subjected to low voltage, the GILP@MF composite efficiently captures VLAs including nanoscale virus particles through the enhanced electrostatic attraction, especially in facing high humidity bioaerosols exhaled by human body. The filtration/collection efficiency and quality factor can reach 98.3% and 0.264 Pa^-1 at 0.1 m s^-1, respectively. This innovative filter provides effective VLA protection and offers potential for non-invasive respiratory virus sampling, advancing medical diagnosis efforts.

2024-03-01·ELECTROPHORESIS

Sequenced‐based Rwanda population provides insights into demographic history

Article

作者: Yan, Chunxia ; Miao, Xinyao ; Yu, Huiyun ; Gao, Jiayang ; Li, Bowen ; Ma, Tao ; Liang, Zuhuan ; Chang, Liao ; Gong, Xiaojuan ; Shen, Yuesheng ; Li, Shengbin ; Zhang, Bao ; Paul, Gasana

AbstractRwanda is known as the heart of Africa, reflecting the history of the world. Colonization and genocide have led to Rwanda's existing genetic structure. Herein, we used massively parallel sequencing to analyze 296 loci in 185 Rwandans and constructed a database for Rwandan forensic data for the first time. We found the following results: First, forensic parameters demonstrated that all loci were highly informative and could be used for forensic identification and paternity tests in Rwandans. Second, we found that the differences in genetic background between Rwandans and other African populations were similar but slight, as indicated by the massively parallel sequencing panel. Rwandans belonged to the African population and were inseparable from populations from neighboring countries. Also, Rwandans were closer to the European and American populations because of colonization, war, and other reasons. There was no scientific basis for racial classification established by colonization. Further research still needs to be carried out on more loci and larger Rwandan samples.

2023-11-01·American Journal of Obstetrics and Gynecology

Noninvasive preeclampsia prediction using plasma cell–free RNA signatures

Article

作者: Huang, Shang ; Xu, Wenqiu ; Li, Jie ; Zhou, Si ; Zhao, Lijian ; Jiang, Hui ; Yang, Wenzhi ; Zhang, Jianguo ; Peng, Huanhuan ; Zhang, Rui ; Wang, Yunfang ; Sun, Hai-Xi ; Wei, Fengxiang ; Yin, Yanning ; Tian, Peirun ; Xue, Penghao

BACKGROUNDPreeclampsia, especially preterm preeclampsia and early-onset preeclampsia, is a life-threating pregnancy disorder, and the heterogeneity and complexity of preeclampsia make it difficult to predict risk and to develop treatments. Plasma cell-free RNA carries unique information from human tissue and may be useful for noninvasive monitoring of maternal, placental, and fetal dynamics during pregnancy.OBJECTIVEThis study aimed to investigate various RNA biotypes associated with preeclampsia in plasma and to develop classifiers to predict preterm preeclampsia and early-onset preeclampsia before diagnosis.STUDY DESIGNWe performed a novel, cell-free RNA sequencing method termed polyadenylation ligation-mediated sequencing to investigate the cell-free RNA characteristics of 715 healthy pregnancies and 202 pregnancies affected by preeclampsia before symptom onset. We explored differences in the abundance of different RNA biotypes in plasma between healthy and preeclampsia samples and built preterm preeclampsia and early-onset preeclampsia prediction classifiers using machine learning methods. Furthermore, we validated the performance of the classifiers using the external and internal validation cohorts and assessed the area under the curve and positive predictive value.RESULTSWe detected 77 genes, including messenger RNA (44%) and microRNA (26%), that were differentially expressed in healthy mothers and mothers with preterm preeclampsia before symptom onset, which could separate participants with preterm preeclampsia from healthy samples and that played critical functional roles in preeclampsia physiology. We developed 2 classifiers for predicting preterm preeclampsia and early-onset preeclampsia before diagnosis based on 13 cell-free RNA signatures and 2 clinical features (in vitro fertilization and mean arterial pressure), respectively. Notably, both classifiers showed enhanced performance when compared with the existing methods. The preterm preeclampsia prediction model achieved 81% area under the curve and 68% positive predictive value in an independent validation cohort (preterm, n=46; control, n=151); the early-onset preeclampsia prediction model had an area under the curve of 88% and a positive predictive value of 73% in an external validation cohort (early-onset preeclampsia, n=28; control, n=234). Furthermore, we demonstrated that downregulation of microRNAs may play vital roles in preeclampsia through the upregulation of preeclampsia-relevant target genes.CONCLUSIONIn this cohort study, a comprehensive transcriptomic landscape of different RNA biotypes in preeclampsia was presented and 2 advanced classifiers with substantial clinical importance for preterm preeclampsia and early-onset preeclampsia prediction before symptom onset were developed. We demonstrated that messenger RNA, microRNA, and long noncoding RNA can simultaneously serve as potential biomarkers of preeclampsia, holding the promise of prevention of preeclampsia in the future. Abnormal cell-free messenger RNA, microRNA, and long noncoding RNA molecular changes may help to elucidate the pathogenic determinants of preeclampsia and open new therapeutic windows to effectively reduce pregnancy complications and fetal morbidity.

252

项与深圳华大智造科技股份有限公司相关的新闻（医药）

2024-10-31

·PRNewswire

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

SHENZHEN, China, Oct. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Special Mention in the TIME Best Inventions 2024 list. Continue Reading TIME Best Inventions 2024 TIME Best Inventions recognizes products, software, or services that are revolutionizing the world. Curated by a network of TIME editors, the annual list recognizes inventions big and small from around the globe. This year, the DNBSEQ-T20x2 joined the ranks of the world's most groundbreaking products, technologies, and services for its creativity, meaningful innovation, and significant impact on modern healthcare. MGI's DNBSEQ-T20x2 ultra-high-throughput sequencer has garnered prominent interest and attention since its debut in February 2023 for bringing down the cost of genome sequencing to 50,000 WGS per year for under $100 per 30x human genome. It was specifically recognized for its leading-edge applications in biotech and for laying the groundwork for more accessible and cost-effective high-throughput sequencing. By providing scalable genome sequencing capabilities, the DNBSEQ-T20x2 enables researchers to perform large-scale genomic analyses at a reduced cost, thereby opening more doors to delivering research on precision medicine. These capabilities are especially impactful in areas where accurate and affordable sequencing can be leveraged to improve outcomes, such as oncology, rare disease research, and public health initiatives. Since its launch, the DNBSEQ-T20x2 has earned accolades worldwide, including the Edison Award, iF Design Award, R&D 100 Award, BEYOND Healthcare Innovation Award, Biotech Breakthrough Award, and Globee Award. Each of these recognitions demonstrates the DNBSEQ-T20x2's design excellence, technical performance, and transformative potential in the field of life sciences and healthcare. "Being featured as a Special Mention in TIME Best Inventions 2024 is a tremendous honor for MGI. It not only celebrates the fruits of our labor; it reinforces our commitment to pushing the boundaries of innovation in genomic technology," said Duncan Yu, President at MGI. "The DNBSEQ-T20x2 is setting a new standard for sequencing efficiency and accessibility, helping make genomics a foundational tool in healthcare for people around the world." In addition to marking an important milestone for MGI, the DNBSEQ-T20x2's recognition by TIME highlights the broader role of genomics in the future of healthcare. By providing researchers, clinicians, and healthcare professionals with affordable, high-throughput sequencing capabilities, MGI is empowering breakthroughs and advancing precision medicine, early diagnostics, and preventive care for all. * The DNBSEQ-T20x2 Genetic Sequencer is for research use only and could not be used for any diagnostic procedures. SOURCE MGI TECH WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-27

·循因缉药

测序仪厂家福音！GeneDx大规模WGS新生儿筛查初步结果出炉

环球视野，深度视角各位亲爱的股东，大家早上好中午好晚上好。我们此前聊过GeneDx的大规模新生儿WGS筛查项目，彼时他还叫Sema4。这项研究名为GUARDIAN，相关的背景可以戳下面了解一下。 Sema4|目标10万例！北美最大新生儿全基因组测序（WGS）筛查研究启动当然，懒得去看的就简要了解下。这项研究目标入组10万例新生儿，通过全基因组测序（WGS）技术进行测序和解读，更好的为遗传疾病的早诊早治提供解决方案。该项研究，联合了纽约州卫生局、哥伦比亚大学医学中心、纽约长老会医院（NewYork-Presbyterian）和Illumina 当时预计2023年初得出初步结果，没想到...呃，也可能是我没看见。那么，我们就来看看这个初步的结果都有什么值得关注的点。我们将从3个方面来聊聊。 1，研究了个啥？ 2，有啥结论？ 3，意味着啥？ #01 研究了个啥？本次研究是一个多中心、单组、前瞻、观察性临床，总计划入组10万例新生儿，通过WGS技术进行筛查。这次披露的数据入组的参与者是2022年9月到2023年7月份的新生儿，研究人员接触了5555个家庭，最终有4000人签署知情同意参与本次临床试验。众所周知，美国是个移民国家。因此，本次入组的新生儿父母种族很多样，包括亚裔16.5%、黑人25.1%、白人44.7%。那么，研究有什么结论吗？ #02 有啥结论？省流版：WGS大法好！ 4000名参与者中，3.7%有阳性的筛查结果。这里面，大部分无法通过常规新生儿筛查发现。 120名真阳性参与者中，92%获得了确诊，这些疾病并未纳入到常规新生儿筛查中。该研究使用基因组测序来检测255种早发性遗传疾病，其中包括156种已有治疗方法的疾病和99种可能通过治疗相关癫痫或早期干预受益的自选神经发育障碍。这其实回答了我们关注新生儿筛查或者说所有早筛都关心的3个问题：可发现：比常规方法更多、更早发现疾病。可治疗：发现的疾病可以被治疗。可干预：发现的疾病即便不能治疗，但是可以通过早期干预改善生存质量。 #03 意味着啥？测序仪厂商笑开颜，靶向探针厂商冒汗。我们在分析GeneDx 2024Q2财报的时候聊过，从收入上看，WES/WGS的增长率要高于样本数量。这货要么给WES（外显子测序）涨价了，要么提高了WGS的比例。相较于WES之类的靶向捕获测序，新生儿筛查中WGS的优势在今天已经是比较明显了（至少在GeneDx看来）：第一，WGS湿实验简单，只要做个DNA提取建库即可第二，测序价格已经足够便宜，如果GeneDx考虑下华大智造，那么测个100G数据也就100美元嘛。第三，分析技术大提速，WGS数据分析已经很难成为制约交付速度的因素了。第四，相较于WES，WGS在大的结构变异方面有优势。因此，GeneDx选择WGS技术作为主攻方向一点毛病没有。 #04 最后我们总结下：第一，GUARDIAN项目中WGS技术提供了更多的新生儿筛查信息，能够更好的为早干预、早治疗提供依据。第二，随着测序成本和分析技术的改善，WGS技术在新生儿早筛中的应用值得关注。第三，强烈建议国内测序仪厂商跟遗传检测企业合作一把，也整个10万例的临床。 GUARDIAN目前已入组13000名参与者，估计后面还会有更多的研究结果发表，咱们可不能落后啊。最后的最后，别忘了，GeneDx的股票简称是.....WGS... END 啊对对对对，扫描这货能联系到我至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！所有内容均不作为投资建议，信息均来自公开资料。近期文章： 2024年10月28日的北京元素 Thermo Fisher 2024Q3，超预期、下跌与中国啊？Twist玩这么花？丹纳赫Danaher：2024Q3超预期，未来看中国 10x Genomics再败，Bruker笑开了花 10x Genomics：你们对价格战一无所知！相关资料：注1：https://ir.genedx.com/news-releases/news-release-details/groundbreaking-guardian-study-shows-benefits-adding-genome注2：https://jamanetwork-com.libproxy1.nus.edu.sg/journals/jama/article-abstract/2825327

财报临床研究

2024-10-10

·循因缉药

10x Genomics 不及预期

环球视野，深度视角各位亲爱的股东们，大家早上好中午好晚上好。 2024年10月9日，这个日子实在是太重要了... Illumina发布新品，Vizgen与Ultiveu合并...然后10x Genomics不及预期。相信看到这条消息的朋友，心里都会一哆嗦。一般提前公布业绩只有一个原因：出现重大变化。可能超出预期的好，也可能超出预期的差。这一次，10x Genomics不幸踩中后者。这条消息威力有多大呢？在盘后直接把10x Genomics的股价干掉了26%... 那么，哪里不及预期呢？单独看收入，2024Q3 10x Genomics营收1.517亿美元，同比下滑1%。其实问题并不大。最重要的问题（之一），出在空间生物学上。根据初步统计数据，2024Q3 空间生物学设备营收1140万美元，同比下滑49.8%，环比下滑24.3%。试剂方面也没好到哪里去，仅仅比上一个季度略微增长1.5%，同比的话去年基数较低，就不需要看了。这确实要远逊于Q2的表现，在空间生物学仪器方面在今年呈现出了一边倒的下跌趋势... 这确实让人心碎。另外，本季度美国区表现拉跨，只拿到了8780万美元的营收，也是不及上个季度。但是很有可能是暂时性的，需要继续观察。真正让花街胆寒的，是后面这一句：将在财报会上讨论2024全年财务指引。这要是往高了调，我不信还要拿出来讨论。在过去的3个季度，10x Genomics大约完成了4.458亿美元的营收。而，2024Q2公布的预期是6.4-6.6亿美元。这意味着，差不多Q4要干2亿美元才能够到及格线。不是说不可能，只是这种可能性有点低了。我们推测，10x Genomics可能把全年财务预期调整到6.2-6.4亿美元之间。当然这一切，还得看10月29日财报会的情况... END 啊对对对对，扫描这货能联系到我至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！所有内容均不作为投资建议，信息均来自公开资料。近期文章： Illumina的“一大步”，竟然是跟随华大智造？贺建奎老师去搞AD（阿尔茨海默病）疫苗了？ miRNA研究者获得2024年诺贝尔生理或医学奖 Cassava离得谱中谱，方为人上人 NGS/NIPT谁能斩获2024诺奖？相关资料：注1：https://investors.10xgenomics.com/news/news-details/2024/10x-Genomics-Announces-Preliminary-Select-Third-Quarter-2024-Results/default.aspx

财报疫苗

100 项与深圳华大智造科技股份有限公司相关的药物交易

登录后查看更多信息

100 项与深圳华大智造科技股份有限公司相关的转化医学

登录后查看更多信息